SCHEMBL2385647

SCHEMBL2385647

CS(=O)(=O)OCC(OCCCCOCc1ccccc1)[C@@H]1CO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
GBA1 P04062 2/20 0.35
UGCG Q16739 2/20 0.35
GBA2 Q9HCG7 2/20 0.35
EPHX2 P34913 2/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PLA2G10 O15496 1/20 0.34
PLA2G2A P14555 1/20 0.34
SOAT1 P35610 1/20 0.33
KCNA3 P22001 1/20 0.33
KCNA5 P22460 1/20 0.33
SPHK1 Q9NYA1 1/20 0.33
MAPT P10636 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385640 1.00 NAAA (0.36) NAAAL3MBTL1TDP1GBA1UGCG
SCHEMBL2384378 0.98 NAAA (0.38) NAAAL3MBTL1TDP1GBA1UGCG
SCHEMBL2384373 0.98 NAAA (0.38) NAAAL3MBTL1TDP1GBA1UGCG
SCHEMBL2385224 0.87 CA1 (0.37) MEN1KMT2AMAPTCA1CA2
SCHEMBL2385217 0.87 CA1 (0.37) MEN1KMT2AMAPTCA1CA2
SCHEMBL2385178 0.78 CA1 (0.36) POLBCA1CA2CA9
SCHEMBL2385181 0.78 CA1 (0.36) POLBCA1CA2CA9
SCHEMBL2385183 0.78 CA1 (0.36) POLBCA1CA2CA9
SCHEMBL2385550 0.78 CA1 (0.36) POLBCA1CA2CA9
SCHEMBL2385554 0.78 CA1 (0.36) POLBCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 NAAA 1407/4885L3MBTL1 2750/4885TDP1 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.